

GENTICEL SIGNS A LIQUIDITY CONTRACT WITH ODDO CORPORATE FINANCE

Genticel (FR0011790542), a French biotechnology company and specialist in the development of therapeutic vaccines, announces that it has entrusted to ODDO CORPORATE FINANCE the setting up of a liquidity contract.

Genticel has entrusted from May 5th, 2014 to December 31st, 2014 (hereafter the contract will be yearly renewable by tacit agreement) to ODDO CORPORATE FINANCE the setting up of a liquidity contract which complies with the Code of Conduct established by AMAFI and is approved by a decision of the AMF dated on March 21st, 2011.

For the setting up of this contract, GENTICEL allocated to the liquidity account the amount of:

- € 200.000.

About Genticel

GENTICEL is a French pharmaceutical company, specialising in the development of therapeutic vaccines aimed at eliminating, at an early stage, the human papillomavirus (HPV) responsible for cervical cancer.

GENTICEL is developing the first-ever therapeutic vaccine, currently in Phase II clinical trials, aimed at eliminating cervical cells infected by type 16 and/or 18 HPV virus. A second therapeutic vaccine candidate targeting six of the most pertinent strains of HPV is currently in preclinical stage. Over many years of R&D, the Company also has a technological platform, Vaxiclase, ideally adapted for developing early-intervention immunotherapies against multiple infectious or cancerous diseases.

Based in Paris and Toulouse, Genticel was awarded the 2013 Innovation Prize by the Grands Prix de l'Economie.

GENTICEL CONTACT
Benedikt Timmerman
Chief Executive Officer
investors@genticel.com

INVESTORS CONTACT
Corinne Puissant
Edouard de Maissin

Tel: +33 (0)1 53 67 35 71
genticel@actus.fr

PRESS CONTACT
Alexandra Prisa

Tel: +33 (0)1 53 67 35 79
aprisa@actus.fr